OTCMKTS:IMUC

EOM Pharmaceuticals (IMUC) Stock Price, News & Analysis

$0.20
0.00 (0.00%)
(As of 04/22/2024 ET)
Today's Range
$0.17
$0.20
50-Day Range
$0.11
$0.30
52-Week Range
$0.11
$0.40
Volume
1,707 shs
Average Volume
5,523 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IMUC stock logo

About EOM Pharmaceuticals Stock (OTCMKTS:IMUC)

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

IMUC Stock Price History

IMUC Stock News Headlines

EOM Pharmaceuticals (OTCMKTS:IMUC) Shares Up 17.3%
ImmunoCellular Therapeutics, Ltd. (IMUC)
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
EOM Pharmaceutical Holdings Inc.
Oramed Pharmaceuticals Inc ORMP
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Analyst Ratings for Olema Pharmaceuticals
Q2 2023 PAVmed Inc Earnings Call
8-K: Acumen Pharmaceuticals, Inc.
OliX Pharmaceuticals Inc (226950)
EOM Pharmaceuticals Holdings, Inc. (IMUC)
See More Headlines
Receive IMUC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EOM Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/13/2018
Today
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:IMUC
Employees
3
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.37
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Irach B. Taraporewala B.S. (Age 68)
    M.S., Ph.D., CEO, President & Director
    Comp: $265.65k
  • Mr. Wayne I. Danson CPA (Age 70)
    CFO & Treasurer
    Comp: $150k
  • Mr. Eli Goldberger (Age 34)
    Founder, Chairman & COO
  • Dr. Shalom Z. Hirschman M.D. (Age 88)
    Co-Founder, Chief Scientific Officer & Medical Director

IMUC Stock Analysis - Frequently Asked Questions

How have IMUC shares performed in 2024?

EOM Pharmaceuticals' stock was trading at $0.2320 at the beginning of the year. Since then, IMUC shares have decreased by 14.7% and is now trading at $0.1980.
View the best growth stocks for 2024 here
.

How were EOM Pharmaceuticals' earnings last quarter?

EOM Pharmaceuticals Holdings, Inc. (OTCMKTS:IMUC) posted its quarterly earnings results on Monday, August, 13th. The company reported ($0.01) earnings per share (EPS) for the quarter.

How do I buy shares of EOM Pharmaceuticals?

Shares of IMUC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:IMUC) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners